Company Filing History:
Years Active: 2020
Title: Salka Elboel Rasmussen: Innovator in EGF(A) Analogues
Introduction
Salka Elboel Rasmussen is a prominent inventor based in Vaerloese, Denmark. She has made significant contributions to the field of pharmaceuticals, particularly through her innovative work on EGF(A) analogues. Her research focuses on developing compounds that can aid in the treatment of various health conditions.
Latest Patents
Salka holds one patent for her invention titled "EGF(A) analogues with fatty acid substituents." This invention relates to compounds derived from the EGF(A) domain of LDL-R. Specifically, it includes compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence, along with at least one substituent that contains a fatty acid group. The patent also covers a pharmaceutical composition and its use as a medicament. The novel EGF(A) compounds are particularly useful in treating conditions such as cholesterol lowering, dyslipidaemia, and cardiovascular disease.
Career Highlights
Salka is currently associated with Novo Nordisk A/S, a leading global healthcare company. Her work at Novo Nordisk has allowed her to focus on innovative solutions in the pharmaceutical industry.
Collaborations
Salka has collaborated with notable colleagues, including Jianhe Chen and Jesper F Lau. These collaborations have further enhanced her research and development efforts in the field.
Conclusion
Salka Elboel Rasmussen is a trailblazer in the development of EGF(A) analogues, contributing valuable innovations to the pharmaceutical industry. Her work has the potential to significantly impact the treatment of cardiovascular diseases and related health issues.